Parkinson's disease
- PMID: 25904081
- DOI: 10.1016/S0140-6736(14)61393-3
Parkinson's disease
Abstract
Parkinson's disease is a neurological disorder with evolving layers of complexity. It has long been characterised by the classical motor features of parkinsonism associated with Lewy bodies and loss of dopaminergic neurons in the substantia nigra. However, the symptomatology of Parkinson's disease is now recognised as heterogeneous, with clinically significant non-motor features. Similarly, its pathology involves extensive regions of the nervous system, various neurotransmitters, and protein aggregates other than just Lewy bodies. The cause of Parkinson's disease remains unknown, but risk of developing Parkinson's disease is no longer viewed as primarily due to environmental factors. Instead, Parkinson's disease seems to result from a complicated interplay of genetic and environmental factors affecting numerous fundamental cellular processes. The complexity of Parkinson's disease is accompanied by clinical challenges, including an inability to make a definitive diagnosis at the earliest stages of the disease and difficulties in the management of symptoms at later stages. Furthermore, there are no treatments that slow the neurodegenerative process. In this Seminar, we review these complexities and challenges of Parkinson's disease.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Similar articles
-
Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.Brain. 2005 Nov;128(Pt 11):2654-64. doi: 10.1093/brain/awh584. Epub 2005 Jul 6. Brain. 2005. PMID: 16000336
-
Overview of Parkinson's disease.Pharmacotherapy. 2007 Dec;27(12 Pt 2):155S-160S. doi: 10.1592/phco.27.12part2.155S. Pharmacotherapy. 2007. PMID: 18041935 Review.
-
Parkinson's disease: Autoimmunity and neuroinflammation.Autoimmun Rev. 2016 Oct;15(10):1005-11. doi: 10.1016/j.autrev.2016.07.022. Epub 2016 Aug 4. Autoimmun Rev. 2016. PMID: 27497913 Review.
-
Heredity in Parkinson's disease: new findings.Isr Med Assoc J. 2001 Jun;3(6):435-8. Isr Med Assoc J. 2001. PMID: 11433638 Review.
-
Parkinson's disease.Acta Clin Croat. 2009 Sep;48(3):377-80. Acta Clin Croat. 2009. PMID: 20055267 Review.
Cited by
-
Microglial Melatonin Receptor 1 Degrades Pathological Alpha-Synuclein Through Activating LC3-Associated Phagocytosis In Vitro.CNS Neurosci Ther. 2024 Oct;30(10):e70088. doi: 10.1111/cns.70088. CNS Neurosci Ther. 2024. PMID: 39444113 Free PMC article.
-
Exercise, Neuroprotective Exerkines, and Parkinson's Disease: A Narrative Review.Biomolecules. 2024 Sep 30;14(10):1241. doi: 10.3390/biom14101241. Biomolecules. 2024. PMID: 39456173 Free PMC article. Review.
-
Amyloid related cerebral microbleed and plasma Aβ40 are associated with cognitive decline in Parkinson's disease.Sci Rep. 2021 Mar 29;11(1):7115. doi: 10.1038/s41598-021-86617-0. Sci Rep. 2021. PMID: 33782518 Free PMC article.
-
Regulation of ABC efflux transporters at blood-brain barrier in health and neurological disorders.Brain Res. 2015 Dec 2;1628(Pt B):298-316. doi: 10.1016/j.brainres.2015.07.005. Epub 2015 Jul 15. Brain Res. 2015. PMID: 26187753 Free PMC article. Review.
-
Biomarkers and the Role of α-Synuclein in Parkinson's Disease.Front Aging Neurosci. 2021 Mar 23;13:645996. doi: 10.3389/fnagi.2021.645996. eCollection 2021. Front Aging Neurosci. 2021. PMID: 33833675 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical